Can-Fite Biopharma Ltd (AMEX:CANF) will be discussing 3Q20 financial results with the investment community.on 30th November 2020 at 9:15 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.canfite.co.il
Earnings Expectation
Can-Fite Biopharma Ltd is reporting third quarter earnings results on Monday 30th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.24 per share from $ 0.25 million in revenue. For the full year, analysts predict revenues of $ 0.90 million, while looking forward to loss of $ 2.92 per share.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The companys lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.
